290 related articles for article (PubMed ID: 28164090)
1. MET: roles in epithelial-mesenchymal transition and cancer stemness.
Jeon HM; Lee J
Ann Transl Med; 2017 Jan; 5(1):5. PubMed ID: 28164090
[TBL] [Abstract][Full Text] [Related]
2. Update on Epithelial-Mesenchymal Plasticity in Cancer Progression.
Fontana R; Mestre-Farrera A; Yang J
Annu Rev Pathol; 2024 Jan; 19():133-156. PubMed ID: 37758242
[TBL] [Abstract][Full Text] [Related]
3. Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.
Lee SY; Jeong EK; Ju MK; Jeon HM; Kim MY; Kim CH; Park HG; Han SI; Kang HS
Mol Cancer; 2017 Jan; 16(1):10. PubMed ID: 28137309
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming during epithelial to mesenchymal transition under the control of TGFβ.
Tan EJ; Olsson AK; Moustakas A
Cell Adh Migr; 2015; 9(3):233-46. PubMed ID: 25482613
[TBL] [Abstract][Full Text] [Related]
5. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
Sylvester PW
Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
[TBL] [Abstract][Full Text] [Related]
6. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis.
Chen T; You Y; Jiang H; Wang ZZ
J Cell Physiol; 2017 Dec; 232(12):3261-3272. PubMed ID: 28079253
[TBL] [Abstract][Full Text] [Related]
8. Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
Hsieh YS; Liao CH; Chen WS; Pai JT; Weng MS
J Cell Biochem; 2017 Dec; 118(12):4639-4651. PubMed ID: 28485480
[TBL] [Abstract][Full Text] [Related]
9. The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation.
Yeo CD; Kang N; Choi SY; Kim BN; Park CK; Kim JW; Kim YK; Kim SJ
Korean J Intern Med; 2017 Jul; 32(4):589-599. PubMed ID: 28704917
[TBL] [Abstract][Full Text] [Related]
10. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
Ma X; Wang B; Wang X; Luo Y; Fan W
PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
[TBL] [Abstract][Full Text] [Related]
11. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
[TBL] [Abstract][Full Text] [Related]
12. The epithelial to mesenchymal transition in pancreatic cancer: A systematic review.
Beuran M; Negoi I; Paun S; Ion AD; Bleotu C; Negoi RI; Hostiuc S
Pancreatology; 2015; 15(3):217-25. PubMed ID: 25794655
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma.
Jayachandran A; Dhungel B; Steel JC
J Hematol Oncol; 2016 Aug; 9(1):74. PubMed ID: 27578206
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-mesenchymal plasticity-engaging stemness in an interplay of phenotypes.
Chin VL; Lim CL
Stem Cell Investig; 2019; 6():25. PubMed ID: 31559312
[TBL] [Abstract][Full Text] [Related]
15. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
16. Targeting EMT in cancer: opportunities for pharmacological intervention.
Davis FM; Stewart TA; Thompson EW; Monteith GR
Trends Pharmacol Sci; 2014 Sep; 35(9):479-88. PubMed ID: 25042456
[TBL] [Abstract][Full Text] [Related]
17. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.
Ren D; Wang M; Guo W; Zhao X; Tu X; Huang S; Zou X; Peng X
Int J Oncol; 2013 Apr; 42(4):1473-81. PubMed ID: 23404342
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers.
Chan TS; Shaked Y; Tsai KK
Front Oncol; 2019; 9():688. PubMed ID: 31417869
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: An update.
Gurzu S; Turdean S; Kovecsi A; Contac AO; Jung I
World J Clin Cases; 2015 May; 3(5):393-404. PubMed ID: 25984514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
